Jiezhong Chen
Immunology · 2016
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 31 citations into it
- Oncology — 31 citations into it
Whom Jiezhong Chen trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Jiezhong Chen's perspective
Ordered by how strongly the researchers Jiezhong Chen trusts endorse each paper. Same corpus, a different order for every researcher.
- The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
- The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection (Nature Immunology)
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells (Science Translational Medicine)
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (Journal of Experimental Medicine)
- Programmed death ligand-1 expression in non-small cell lung cancer (Laboratory Investigation)
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (New England Journal of Medicine)
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer (Proceedings of the National Academy of Sciences of the United States of America)
Their papers
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer. (2016) — 726 citations